

Amend Senate S8307, Assembly A8807, AN ACT to amend part H of chapter 59 of the laws of 2011, amending the public health law and other laws relating to general hospital reimbursement for annual rates, in relation to known and projected department of health state fund medicaid expenditures...

Page	Line	Amendment
Page 4,	Unnumbered lines 34 through 37 (AN ACT CLAUSE),	Strike out "to amend part NN of chapter 57 of the laws of 2018 amending the public health law and other laws relating to enacting the opioid stewardship act, in relation to making the opioid stewardship fund permanent" Insert "intentionally omitted"
Page 5,	Unnumbered Line 7	After "(Part EE;)" strike out "and"
Page 5,	Unnumbered Line 8	After "(Part FF)" insert "; to amend the social services law, in relation to providing contracting flexibility in relation to 1115 medicaid waivers (Part GG); and to amend the social services law, in relation to the removal of the fiscal intermediary procurement and replacing it with an authorization process; to amend the public health law, in relation to eliminating conflicts of interest between consumer directed personal assistance program fiscal intermediaries and licensed home care services agencies; to amend the social services law, in relation to the consumer directed personal assistance program; and to repeal certain provisions of the social services law relating thereto (Part HH)"
Page 5,	Line 4,	After "through" strike out "FF" and insert "HH"
Page 15,	Line 45,	After " <u>twenty-four,</u> " and insert " <u>the case mix adjustment from</u> "
Page 15,	Line 47,	After " <u>from the</u> " strike out " <u>January two thousand twenty four</u> " and insert " <u>July two thousand twenty-three</u> "
Page 21,	Between lines 8 and 9,	Insert "§3. Paragraph (a) of subdivision 1 of section 3614-f of the public health law, as added by section 3 of part NN of chapter 57 of the laws of 2023, is amended to read as follows: (a) "Home care aide" [shall have the same meaning as defined in section thirty-six hundred fourteen-c of this article] means, for the purpose of this section, a home health aide, personal care aide, home attendant, personal assistant performing consumer directed personal assistance services pursuant to section three hundred sixty-five-f of the social services law, or other licensed or unlicensed person whose primary responsibility includes the provision of in-home assistance with activities of daily living, instrumental activities of daily living or health-related tasks; provided, however, that home care aide

		does not include any individual (i)working on a casual basis, or (ii) (except for a person employed under the consumer directed personal assistance program under section three hundred sixty-five-f of the social services law) who is a relative through blood, marriage or adoption of: (1) the employer; or (2) the person for whom the worker is delivering services, under a program funded or administered by federal, state or local government."
Page 21,	Line 9,	After "\$" strike out "3" and insert "4"
Page 22,	Line 3,	After "(a)" strike out "The" and insert "the"
Page 22,	Line 3,	After "(a)" insert " <u>Notwithstanding sections one hundred twelve and one hundred sixty-three of the state finance law, sections one hundred forty-two and one hundred forty-three of the economic development law, and any other inconsistent provision of law,</u> "
Page 22,	Line 10,	After "however," insert " <u>notwithstanding sections one hundred twelve and one hundred sixty-three of the state finance law, sections one hundred forty-two and one hundred forty-three of the economic development law, and any other inconsistent provision of law,</u> "
Page 22,	Line 10,	After "however," strike out "that"
Page 24,	Line 1,	After "(v)" insert " <u>Awards and contracting.</u> "
Page 24,	Line 34,	After "(b)" insert " <u>Transitioning the managed care program.</u> <u>(i) Within sixty-days of the department issuing the request for proposals under paragraph (a) of this subdivision, a managed care provider that was approved to participate in the managed care program prior to the issuance of the request for proposals, shall submit its intention to complete such proposal to the department.</u> <u>(ii) A managed care provider that: (A) fails to submit its intent timely, (B) indicates within the sixty-days its intent not to complete such a proposal, (C) fails to submit a proposal within the further timeframe specified by the commissioner in the request for proposals, or (D) is not awarded the ability to participate in the managed care program under paragraph (a) of this subdivision, shall, upon direction from the commissioner, terminate its services and operations in accordance with the contract between the managed care provider and the department and shall be additionally required to maintain coverage of participants for such period of time as determined necessary by the commissioner to achieve the safe and orderly transfer of participants.</u> <u>(c) Addressing needs for additional managed care providers to ensure participant access and choice."</u>

Page 24,	Line 44,	Strike out " <u>(c)</u> " and insert " <u>(d)</u> "
Page 24,	Line 49,	Strike out " <u>(d)</u> " and insert " <u>(e)</u> "
Page 24,	Line 51,	Strike out " <u>(e)</u> " and insert " <u>(f)</u> "
Page 24,	Line 51,	Strike out " <u>(d)</u> " and insert " <u>(e)</u> "
Page 25,	Line 11,	Before "An eligible applicant shall" insert " <u>Certificate of Authority; form.</u> "
Page 28,	Line 41,	After " <u>(v)</u> " insert " <u>Award and contracting.</u> "
Page 29,	Line 19,	After " <u>(b)</u> " insert " <u>Transitioning enrollees who are eligible under title XIX of the federal social security act (i) Within sixty-days of the department issuing the request for proposals under paragraph (a) of this subdivision, a managed long term care plan that was approved to provide health and long term care services to enrollees who are eligible under title XIX of the federal social security act prior to the issuance of the request for proposals, shall submit its intention to complete such proposal to the department. (ii) A managed long term care plan that: (A) fails to submit its intent timely; (B) indicates within the sixty-days its intent not to complete such a proposal, (C) fails to submit a proposal within the further timeframe specified by the commissioner in the request for proposals, or (D) is not awarded the ability to provide health and long term care services to enrollees who are eligible under title XIX of the federal social security act under paragraph (a) of this subdivision, shall, upon direction from the commissioner, terminate its services and operations in accordance with the contract between the managed long term care plan and the department and shall be additionally required to maintain coverage of enrollees for such period of time as determined necessary by the commissioner to achieve the safe and orderly transfer of enrollees.</u> (c)"
Page 29,	Line 31,	Before "(d)" strike out "[" and after "(d)" strike out "]" <u>(c)</u> "
Page 30,	Line 11,	Before "(e)" strike out "[" and after "(e)" strike out "For the duration of the moratorium under paragraph (d) of this subdivision (d)]
Page 31,	Line 20,	After "the" strike out " <u>notice</u> " and insert " <u>statement of damages</u> "
Page 31,	Lines 32 through 36,	After "d(i)" strike out " <u>To dispute liquidated damages imposed by this subdivision the to the commissioner within thirty calendar days from the date of the statement of damages. Such dispute shall be made in the form and manner prescribed by the commissioner</u> " and

		insert <u>"A managed care organization may dispute the imposition of liquidated damages in writing, and in the form and manner prescribed by the commissioner, within thirty calendar days from the date of the statement of damages"</u>
Page 31,	Lines 37 and 38	After <u>"(ii)"</u> strike out <u>"The department will deny any disputes that are not delivered in the format and timeframe specified by the department"</u> and insert <u>"Disputes that are not delivered in the format and timeframe specified by the department shall be denied by the department and deemed waived by the managed care organization"</u>
Page 31,	Lines 39 through 46,	After <u>"(iii)"</u> strike out <u>"The managed care organization waives any dispute not raised within thirty calendar days of issuance of the statement of damages. It also waives any arguments it fails to raise in writing within thirty calendar days of issuance of the statement of damages, and waives the right to use any materials, data, and/or information not contained in or accompanying the managed care organization's submission submitted within the thirty calendar days of issuance of the statement of damages in any subsequent legal or administrative proceeding"</u> and insert <u>"A managed care organization shall waive any arguments, materials, data, and information not contained in or accompanying a timely submitted written dispute, including for use in any subsequent legal or administrative proceeding"</u>
Pages 31 and 32,	Lines 51 through 4,	After <u>"(e)"</u> strike out <u>"For purposes of this subdivision a violation shall mean a determination by the commissioner that the managed care organization failed to act as required under the model contract or applicable federal and state statutes, rules or regulations governing managed care organization. For the purposes of this subdivision, each day that an ongoing violation continues shall be a separate violation. In addition, each instance of failing to furnish necessary and/or required medical services or items to each enrollee shall be a separate violation. As well, each day that the managed care organization fails to furnish necessary and/or required medical services or items to enrollees shall be a separate violation"</u> and insert <u>"For purposes of this subdivision a violation shall mean: (i) a determination by the commissioner that the managed care organization failed to act as required under the model contract or applicable federal and state statutes, rules or regulations governing managed care organization; (ii) each instance of a managed care organization failing to furnish necessary and/or required medical services or items to each enrollee shall be a separate violation. For the purposes of this subdivision, each day that an ongoing violation continues shall be a separate violation"</u>

Page 46,	Between lines 42 and 43,	<p>Insert “§ 8. Section 268 of the public health law, as added by section 2 of part T of chapter 57 of the laws of 2019, is amended to read as follows:</p> <p>The purpose of this title is to codify the establishment of the health benefit exchange in New York, known as NY State of Health, The Official Health Plan Marketplace (Marketplace), in conformance with Executive Order 42 (Cuomo) issued April 12, 2012. The Marketplace shall continue to perform eligibility determinations for federal and state insurance affordability programs including medical assistance in accordance with section three hundred sixty-six of the social services law, child health plus in accordance with section twenty-five hundred eleven of this chapter, the basic health program in accordance with section three hundred sixty-nine-gg of the social services law, <u>the 1332 state innovation program in accordance with section three hundred sixty-nine-ii of the social service law</u>, and premium tax credits and cost-sharing reductions, together with performing eligibility determinations for qualified health plans and such other health insurance programs as determined by the commissioner. The Marketplace shall also facilitate enrollment in insurance affordability programs, qualified health plans and other health insurance programs as determined by the commissioner, the purchase and sale of qualified health plans and/or other or additional health plans certified by the Marketplace pursuant to this title, and shall continue to have the authority to operate a small business health options program (“SHOP”) to assist eligible small employers in selecting qualified health plans and/or other or additional health plans certified by the Marketplace and to determine small employer eligibility for purposes of small employer tax credits. It is the intent of the legislature, by codifying the Marketplace in state statute, to continue to promote quality and affordable health coverage and care, reduce the number of uninsured persons, provide a transparent marketplace, educate consumers and assist individuals with access to coverage, premium assistance tax credits and cost-sharing reductions. In addition, the legislature declares the intent that the Marketplace continue to be properly integrated with insurance affordability programs, including Medicaid, child health plus and the basic health program, <u>the 1332 state innovation program</u>, and such other health insurance programs as determined by the commissioner.</p>
----------	--------------------------	---

		<p>§ 9. Subdivision 8 of section 268-a of the public health law, as added by section 2 of part T of chapter 57 of the laws of 2019, is amended to read as follows:</p> <p>8. "Insurance affordability program" means Medicaid, child health plus, the basic health program, <u>the 1332 state innovation program</u>, post-partum extended coverage and any other health insurance subsidy program designated as such by the commissioner."</p>
Page 46,	Line 43,	After "\$" strike out "8" insert " <u>10</u> "
Page 46,	Lines 45 and 46,	After "however," strike out "that sections four, five, six, and seven of this act shall take 46 effect January 1, 2025; provided, further,"
Page 70,	Line 36,	After "committee" insert "[" and after "or" insert "]"."
Page 72,	Between lines 43 and 44,	<p>Insert "<u>§ 5. Section 2504 of the public health law is amended by adding a new subdivision 8 to read as follows:</u></p> <p><u>8. Drug, cannabis, or alcohol testing for pregnant or postpartum individuals.</u></p> <p><u>(a) Definition. As used in this subdivision, "test" shall mean a test using a biological sample, including, but not limited to, urine, blood, or hair, for the presence of drugs, cannabis, or alcohol.</u></p> <p><u>(b) Unless legally authorized to do so, no health care professional licensed, certified, or authorized under title eight of the education law shall:</u></p> <p><u>(i) perform a drug, cannabis, or alcohol test on a person who is pregnant or up to one year postpartum unless:</u></p> <p><u>(A) the pregnant or postpartum patient gives prior verbal or written informed consent specific to the drug, cannabis, or alcohol test; and</u></p> <p><u>(B) the performance of the drug, cannabis, or alcohol test is within the scope of medical care being provided to the patient.</u></p> <p><u>(c) Verbal or written informed consent to a drug, cannabis, or alcohol test pursuant to this subdivision shall occur prior to administration, in language understandable to the pregnant or postpartum patient, under circumstances that provide such person sufficient opportunity to consider whether or not to authorize the drug, cannabis, or alcohol test and minimize the possibility of coercion or undue influence, and shall consist of verbal authorization memorialized in the medical record or written authorization that is dated and signed. Such authorization shall include the following:</u></p>

		<p><u>(i) a statement explaining that consenting to a drug, cannabis, or alcohol test is voluntary and requires written or verbal informed consent, except when conditions under subdivision four of this section or paragraph (d) of this subdivision are met;</u></p> <p><u>(ii) a statement that testing positive for drugs, cannabis, or alcohol could have legal consequences;</u></p> <p><u>(iii) a statement explaining the extent of confidentiality of the test results;</u></p> <p><u>(iv) a statement of the medical purpose of the test; and</u></p> <p><u>(v) a general description of the test.</u></p> <p><u>(d) Drug, cannabis, or alcohol testing pursuant to this subdivision may be performed without consent of the patient when, in the health care professional's judgment, an emergency exists and the patient is in immediate need of medical attention, and an attempt to secure consent would result in delay of treatment that could increase the risk to the patient's life or health. In the case that drug, cannabis, or alcohol testing is performed under these circumstances, the results shall be discussed with the patient, in language understandable to the patient and shall consist of verbal notification or written notification that is dated, signed, and includes the following:</u></p> <p><u>(i) a statement that testing positive for drugs, cannabis, or alcohol could have legal consequences;</u></p> <p><u>(ii) a statement in the medical record with a description of the emergency that necessitated unconsented drug, cannabis, or alcohol testing; and</u></p> <p><u>(iii) a statement explaining the extent of confidentiality of the results.</u></p> <p><u>(e) Nothing in this section shall diminish any other requirement to obtain informed consent for a drug, cannabis, or alcohol test or any other procedure."</u></p>
Page 72,	Line 44,	After "\$" strike out "5" insert "6"
Page 113,	Line 50,	After "both." strike out "A" and insert "Any application for this program must be jointly submitted by a"
Page 113,	Line 50,	After "and" strike out "a" and insert "at least one"

Page 113,	Line 51,	After " <u>organization</u> " strike out " <u>may jointly apply for this program</u> "
Page 114,	Line 31,	After " <u>with</u> " strike out " <u>article</u> " and insert " <u>section</u> "
Page 119,	Line 49,	Before "new" strike out "two" and insert "a" and after "new" strike out "subdivisions" and insert "subdivision" and after "42" strike out "and 43"
Page 120,	Lines 8 through 11,	Strike out "43. " <u>"Patient identifying information" means information or direct identifiers and demographic information that can be used to readily identify a particular patient as may be specified in more detail in regulations promulgated by the commissioner.</u> "
Page 120,	Lines 46 and 47,	After "formula" strike out " <u>or possesses patient identifying information</u> "
Page 121,	Line 5,	After "(e)" insert " <u>to</u> "
Page 121,	Line 26,	After " <u>program</u> " insert " <u>registry</u> "
Page 121,	Line 39,	After " <u>surveillance</u> " insert " <u>,</u> "
Page 121,	Line 40,	After " <u>outreach:</u> " insert a line break
Page 121,	Line 42,	After "commissioner;" insert a line break
Page 121,	Line 44,	After "protected;" insert a line break
Page 121,	Line 45,	After "and" insert a line break
Page 122,	Lines 7 and 8,	After "(93)" strike out " <u>Zipeprol(1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-yl]-1-phenylpropan-2-ol).</u> " and insert " <u>1-methoxy-3-{4-(2-methoxy-2-phenylethyl)piperazin-1-yl}-1-phenylpropan-2-ol. Other name: Zipeprol</u> "
Page 122,	Line 10,	After " <u>than-1-amine.</u> " strike out " <u>Some trade or other names</u> " and insert " <u>Other names</u> "
Page 122,	Lines 11 and 12,	After "(95)" strike out " <u>meta-fluorofentanyl (N-(3-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide)</u> " and insert " <u>meta-Fluorofentanyl (N-(3-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide)</u> "

Page 122,	Lines 13 and 14,	After " <u>(96)</u> " strike out " <u>meta-fluoroisobutyryl fentanyl(N-(3-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide)</u> " and insert " <u>meta-Fluoroisobutyryl fentanyl (N-(3-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide)</u> "
Page 122,	Line 15,	After " <u>(97)</u> " strike out " <u>para-methoxyfuranyl</u> " and insert " <u>para-Methoxyfuranyl</u> "
Page 122,	Lines 17 and 18,	After " <u>(98)</u> " strike out " <u>3-furanyl fentanyl(N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-3-carboxamide)</u> " and insert " <u>3-furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-3-carboxamide)</u> "
Page 122,	Lines 19 and 20,	After " <u>(99)</u> " strike out " <u>2',5'-dimethoxyfentanyl(N-(1-(2,5-dimethoxyphenethyl)piperidin-4-yl)-N-phenylpropionamide)</u> " and insert " <u>2',5'-Dimethoxyfentanyl (N-(1-(2,5-dimethoxyphenethyl)piperidin-4-yl)-N-phenylpropionamide)</u> "
Page 122,	Lines 21 and 22,	After " <u>(100)</u> " strike out " <u>Isovaleryl fentanyl(3-methyl-N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide)</u> " and insert " <u>Isovaleryl fentanyl (3-methyl-N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide)</u> "
Page 122,	Lines 23 and 24,	After " <u>(101)</u> " strike out " <u>ortho-fluorofuranyl fentanyl(N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide).</u> " and insert " <u>ortho-Fluorofuranyl fentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide).</u> "
Page 122,	Line 25 and 26,	After " <u>(102)</u> " strike out " <u>alpha'-methyl butyryl fentanyl(2-methyl-N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide).</u> " and insert " <u>alpha'-Methyl butyryl fentanyl (2-methyl-N-(1-phenethylpiperidin 4-yl)-N-phenylbutanamide).</u> "
Page 122,	Line 27,	After " <u>(103)</u> " strike out " <u>para-methylcyclopropyl</u> " and insert " <u>para-Methylcyclopropyl</u> "
Page 122,	Lines 33 through 35,	After " <u>other names:</u> " strike out " <u>7-ethyl-6, 6&, 7, 8, 9, 10, 12, 13-octahydro-2-methoxy-6, 9-methano-5h-</u>

		pyrido {1',2':1,2}azepino {5,4-b} indole: tabernanthe iboga." and insert "7-Ethyl-6,6&,7,8,9,10,12,13-octahydro-2-methoxy-6, 9-methano-5H-pyrido{1',2':1,2}azepino {5,4-b} indole; Tabernanthe iboga."
Page 122,	Lines 36 and 37,	After "or other" strike out "names:5-methoxy-3-[2-(dimethylamino)ethyl]indole; 5-MeO-DMT" and insert "names: 5-methoxy-3-{2-(dimethylamino)ethyl}indole; 5-MeO-DMT"
Page 123,	Lines 14 and 15,	After "PV8;" strike out "1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one." and insert " 1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one."
Page 123,	Line 16,	After "(54)" strike out "4-Chloro-alpha-pyrrolidinovalerophenone." and insert "4'-Chloro-alpha-pyrrolidinovalerophenone."
Page 123,	Lines 19 and 20,	After "2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one" strike out "(methoxeta-mine, MXE)." and insert "(methoxetamine, MXE)."
Page 123,	Lines 26 and 27,	After "(7)" strike out "4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno{3,2-f}{1,2,4}triazolo{4,3-a}{1,4}diazepine." and insert "4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno{3,2-f}{1,2,4}triazolo{4,3-{alpha}}{1,4}diazepine."
Page 123,	Lines 28 and 29,	After "(8)" strike out "8-chloro-6-(2-fluorophenyl)-1-methyl-4H-benzo{f}{1,2,4}triazolo{4,3-a}{1,4}diazepine." and insert "8-chloro-6-(2-fluorophenyl)-1-methyl-4H-benzo{f}{1,2,4}triazolo{4,3-{alpha}}{1,4}diazepine."
Page 123,	Lines 30 and 31,	After "(9)" strike out "6-(2-chlorophenyl)-1-methyl-8-nitro-4H-benzo{f}{1,2,4}triazolo{4,3-a}{1,4}diazepine." and insert "6-(2-chlorophenyl)-1-methyl-8-nitro-4H-benzo{f}{1,2,4}triazolo{4,3-{alpha}}{1,4}diazepine."
Page 123,	Lines 32 through 34,	After "(10)" strike out "8-bromo-6-(2-fluorophenyl)-1-methyl-4H-benzo{f}{1,2,4}triazolo{4,3-a}{1,4}diazepine (alternate chemical name: 8-bromo-6-(2-fluorophenyl)-1-methyl-4H-{1,2,4}triazolo{4,3-a}{1,4}benzodiazepine)" and insert "8-bromo-6-(2-fluorophenyl)-1-methyl-4H-benzo{f}{1,2,4}triazolo{4,3-{alpha}}{1,4}diazepine."
Page 123,	Lines 44 and 45,	After "names:" strike out "4-fluoro-N-methylcathinone;" and insert "4-fluoro-N-methylcathinone;"
Page 123,	Line 46,	After "(25)" strike out "7-[(10,11-dihydro-5H-dibenzo]a,d[cyclohepten-5-yl)amino]heptanoic" and insert "7-{(10,11-dihydro-5H-dibenzo{a,d}cyclohepten-5-yl)amino}heptanoic"

Page 123,	Lines 50 and 51,	After " <u>name:</u> " strike out " <u>methiopropamine.</u> " and insert " <u>methiopropamine.</u> "
Page 123,	Lines 53 and 54,	After " <u>4,5-dihydro-4-methyl-5-(4-methylphenyl)-2-oxazolamine;</u> " strike out " <u>4-methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine.</u> " and insert " <u>4-methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine.</u> "
Page 124,	Lines 4 and 5,	After "(2)" strike out " <u>{1-(5-fluoro-pentyl)-1H-indol-3-yl} (2,2,3,3-tetramethylcyclopropyl)methanone.</u> " and insert " <u>{1-(5-fluoro-pentyl)-1H-indol-3-yl} (2,2,3,3-tetramethylcyclopropyl)methanone.</u> "
Page 124,	Lines 6 and 7,	After "(6)" strike out " <u>N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazo[-]le-3-carboxamide.</u> " and insert " <u>N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazo[-]le-3-carboxamide.</u> "
Page 124,	Lines 8 and 9,	After "(10)" strike out " <u>{1-(5-fluoropentyl)-1H-indazol-3-yl} (naphthalen-1-[yl]yl)methanone.</u> " and insert " <u>{1-(5-fluoropentyl)-1H-indazol-3-yl} (naphthalen-1-[yl]yl)methanone.</u> "
Page 124,	Lines 18 and 19,	After " <u>MMB-FUBINACA;</u> " strike out " <u>AMB-FUBINA-CA.</u> " and insert " <u>AMBFUBINACA</u> "
Page 124,	Lines 34 and 35,	After "(20)" strike out " <u>N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazol e-3-carboxamide.</u> " and insert " <u>N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazol e-3-carboxamide.</u> "
Page 124,	Lines 37 and 38,	After " <u>4-CN-CUMYL-BUTINACA;</u> " strike out " <u>4-cyano-CUMYL-BUTI- NACA;4-CN-CUMYL BINACA;</u> " and insert " <u>4-cyano-CUMYL-BUTINACA; 4-CN-CUMYL BINACA;</u> "
Page 124,	Lines 44 and 45,	After " <u>4F-MDMB-BINACA;</u> " strike out " <u>4F-MDMB-BUTINA-CA.</u> " and insert " <u>4F-MDMB-BUTINACA.</u> "
Page 124,	Lines 55 and 56,	After "(29)" strike out " <u>(1-4-fluorobenzyl)-1H-indol-3-yl} (2,2,3,3-tetramethylcyclopropyl)methanone.</u> " and insert " <u>(1-(4-fluorobenzyl)-1H-indol-3-yl) (2,2,3,3-tetramethylcyclopropyl)methanone.</u> "
Page 125,	Line 6,	After " <u>nalmefene,</u> " strike out " <u>naloxefol,</u> " and insert " <u>naloxegol,</u> "
Page 125,	Line 30,	Strike out " <u>30.</u> " and insert " <u>(30)</u> "
Page 125,	Lines 37 through 39,	After "(1)" strike out " <u>Nabilone: Another name for nabilone: (+,-)-trans-3-(1,1-dimethylheptyl)-6, 6a, 7, 8, 10, 10a-hexahydro-1-hydroxy-6, 6-dimethyl-9H-dibenzo{b,d}pyran-9-one.</u> " and insert " <u>Nabilone. Another</u> "

		name for nabilone: <u>+,-)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo{b,d}pyran-9-one.</u> "
Page 125,	Line 47 and 48,	After "(i)" strike out "[4-anilino-N-phenethylpiperidine] 4-anilino-N-phenethylpiperidine (ANPP)" and insert " <u>4-anilino-N-phenethylpiperidine (ANPP).</u> "
Page 126,	Line 1,	After "(i)" strike out "3{beta}, 17-dihydroxy-5a-androstane" and insert " <u>3{beta},17{beta}-dihydroxy-5{alpha}-androstane</u> "
Page 126,	Line 2,	After "(ii)" strike out "3{alpha}, 17{beta}-dihydroxy-5a-androstane" and insert " <u>3{alpha},17{beta}-dihydroxy-5{alpha}-androstane</u> "
Page 126,	Lines 8 and 9,	After "4-androstenediol" strike out "(3{beta}, 17{beta}-dihydroxy-androst-4-ene)" and insert " <u>(3{beta},17{beta}-dihydroxy-androst-4-ene)</u> "
Page 126,	Lines 10 and 11,	After "5-androstenediol" strike out "(3{beta}, 17{beta}-dihydroxy-androst-5-ene)" and insert " <u>(3{beta},17{beta}-dihydroxy-androst-5-ene)</u> "
Page 126,	Line 12,	After "1-androstenedione" strike out "({5{alpha}}-androst-1-en-3, 17-dione)" and insert " <u>(5{alpha}-androst-1-en-3,17-dione)</u> "
Page 126,	Lines 15 and 16,	After "Bolasterone" strike out "(7{alpha},17{alpha}-dimethyl-17{beta}-hydroxyandrost-4-en-3-one)" and insert " <u>(7{alpha},17{alpha}-dimethyl-17{beta}-hydroxyandrost-4-en-3-one)</u> "
Page 126,	Line 17,	After "Boldenone" strike out "(17{beta}-hydroxyandrost-1, 4,-diene -3-one)" and insert " <u>(17{beta}-hydroxyandrost-1,4,-diene-3-one)</u> "
Page 126,	Lines 19 and 20,	After "Calusterone" strike out "(7{beta}, 17{alpha}-dimethyl-17{beta}-hydroxyandrost- 4-en-3-one)" insert " <u>(7{beta},17{alpha}-dimethyl-17{beta}-hydroxyandrost-4-en-3-one)</u> "
Page 126,	Line 21,	After "Clostebol" strike out "(4-chloro-17{beta}-hydroxyandrost-4-e n-3-one)" and insert " <u>(4-chloro-17{beta}-hydroxyandrost-4-en-3-one)</u> "
Page 126,	Line 24,	After "(xvii)" strike out "{Delta} 1-dihydrotestosterone" and insert " <u>{Delta}1-dihydrotestosterone</u> "
Page 126,	Lines 32 and 33,	After "Fluoxymesterone" strike out "(9-fluoro-17{alpha}-methyl-11{beta},17 {beta}-dihydroxyandrost-4-en-3-one)" and insert " <u>(9-fluoro-17{alpha}-methyl-11{beta},17{beta}-dihydroxyandrost-4-en-3-one)</u> "

Page 126,	Lines 34 and 35,	After "Formebolone" strike out "(2-formyl-17{alpha}-methyl-11{alpha},17{beta}-dihydroxyandrost-1, 4-dien-3-one)" and insert " <u>(2-formyl-17{alpha}-methyl-11{alpha},17{beta}-dihydroxyandrost-1,4-dien-3-one)</u> "
Page 126,	Lines 36 and 37,	After "Furazabol" strike out "(17{alpha}-methyl-17{beta}-hydroxyandros tano {2, 3-c}-furazan)" and insert " <u>(17{alpha}-methyl-17{beta}-hydroxyandrostano {2,3-c}-furazan)</u> "
Page 126,	Line 38,	After "(xxiv)" strike out "13{beta}-ethyl-17{beta}-hydroxygon-4-en-3-one" and insert " <u>13{beta}-ethyl-17{beta}-hydroxygon-4-en-3-one</u> "
Page 126,	Lines 39 and 40,	After "4-hydroxytestosterone" strike out "(4, 17{beta}-dihydroxy-androst-4-en-3-one)" and insert " <u>(4,17{beta}-dihydroxy-androst-4-en-3-one)</u> "
Page 126,	Lines 41 and 42,	After "4-hydroxy-19-nortestosterone" strike out "(4,17{beta}-dihydroxy-estr-4-en-3-one)" and insert "(4,17{beta}-dihydroxyestr-4-en-3-one)"
Page 126,	Line 43,	After "(xxvii)" strike out "desoxymethyltestosterone" and insert " <u>Desoxymethyltestosterone</u> "
Page 126,	Line 44,	After "a.k.a.," strike out "madol)" and insert " <u>'madol'</u> "
Page 126,	Lines 45 and 46,	After "Mestanolone" strike out "(17{alpha}-methyl-17{beta}- hydroxy- 5-an-drostan-3-one)" and insert " <u>(17{alpha}-methyl-17{beta}-hydroxy-5-androstan-3-one)</u> "
Page 126,	Lines 47 and 48,	After "Mesterolone" strike out "(1{alpha}methyl-17{beta}-hydroxy-{5{alpha}}-androstan-3-one)" and insert " <u>(1{alpha}-methyl-17{beta}-hydroxy-5{alpha}-androstan-3-one)</u> "
Page 126,	Lines 49 and 50,	After "Methandienone" strike out "(17{alpha}-methyl-17{beta}-hydroxyandrost-1, 4-dien-3-one)" and insert " <u>(17{alpha}-methyl-17{beta}-hydroxyandrost-1,4-dien-3-one)</u> "
Page 126,	Lines 51 and 52,	After "Methandriol" strike out "(17{alpha}-methyl-3{beta}, 17{beta}-dihydroxyandrost-5-ene)" and insert " <u>(17{alpha}-methyl-3{beta},17{beta}-dihydroxyandrost-5-ene)</u> "
Page 126,	Line 53 and 54,	After "Methenolone" strike out "(1-methyl- 17{beta}-hydroxy-5 {alpha}-androst- 1-en-3-one)." and insert " <u>Methenolone (1-methyl-17{beta}-hydroxy-5 {alpha}-androst-1-en-3-one).</u> "
Page 126,	Lines 55 and 56,	After "(xxxiii)" strike out "17{alpha}-methyl-3{beta},17{beta}-dihydroxy - 5a-an-drostan-3-one." and

		insert " <u>17{alpha}-methyl-3{beta},17{beta}-dihydroxy-5{alpha}-androstane.</u> "
Page 127,	Lines 1 and 2,	After " <u>(xxxiv)</u> " strike out "17{alpha}-methyl-3{alpha},17{beta}- dihydroxy- 5a-an-drostane" and insert " <u>17{alpha}-methyl-3{alpha},17{beta}-dihydroxy-5{alpha}-androstane</u> "
Page 127,	Lines 3 and 4,	After " <u>(xxxv)</u> " strike out "17{alpha}-methyl-3{beta},17{beta}-dihydroxyandrost-4-ene." and insert " <u>17{alpha}-methyl-3{beta},17{beta}-dihydroxyandrost-4-ene.</u> "
Page 127,	Lines 5 and 6,	After " <u>(xxxvi)</u> " strike out "17{alpha}-methyl-4-hydroxynandrolone (17{alpha}-methyl-4-hydroxy-17{beta}-hydroxyestr-4-en-3-one)." and insert " <u>17{alpha}-methyl-4-hydroxynandrolone (17{alpha}-methyl-4-hydroxy-17{beta}-hydroxyestr-4-en-3-one).</u> "
Page 127,	Lines 7 and 8,	After "Methyldienolone" strike out "(17{alpha}-methyl-17{beta}- hydroxyes-tra- 4,9(10)-dien-3-one)." and insert " <u>(17{alpha}-methyl-17{beta}-hydroxyes-tra-4,9(10)-dien-3-one).</u> "
Page 127,	Lines 9 and 10,	After "Methyltrienolone" strike out "(17{alpha}-methyl-17{beta}-hydroxyestra-4, 9-11-trien-3-one)." and insert " <u>(17{alpha}-methyl-17{beta}-hydroxyestra-4,9-11-trien-3-one).</u> "
Page 127,	Lines 15 and 16,	After " <u>(xli)</u> " strike out "17{alpha}-methyl- Δ 1-dihydrotestosterone (17b{beta}-hydroxy-17{alpha}-methyl-5{alpha}-androst-1-en-3-one)" and insert " <u>17{alpha}-methyl-Δ1-dihydrotestosterone (17{beta}-hydroxy-17{alpha}-methyl-5{alpha}-androst-1-en-3-one)"</u>
Page 127,	Line 18,	After " <u>(xlii)</u> " strike out "Nandrolone(17{beta}-hydroxyestr-4-en-3-one)." and insert " <u>Nandrolone (17{beta}-hydroxyestr-4-en-3-one).</u> "
Page 127,	Lines 19 and 20,	After "19-nor-4-androstenediol" strike out "(3{beta},17{beta}-dihydroxyestr- 4-ene)." and insert " <u>(3{beta},17{beta}-dihydroxyestr-4-ene).</u> "
Page 127,	Lines 21 and 22,	After "19-nor-4-androstenediol" strike out "(3{alpha},17{beta}-dihydrox-yestr-4-ene)." and insert " <u>(3{alpha},17{beta}-dihydroxyestr-4-ene).</u> "
Page 127,	Line 23,	After "19-nor-5-androstenediol" strike out "(3{beta},17{beta}-dihydroxyestr -5-ene)." and insert " <u>(3{beta},17{beta}-dihydroxyestr-5-ene).</u> "
Page 127,	Lines 24 and 25,	After "19-nor-5-androstenediol" strike out "(3{alpha},17{beta}-dihydrox-yestr-5-ene)." and insert " <u>(3{alpha},17{beta}-dihydroxyestr-5-ene).</u> "

Page 127,	Lines 26 and 27,	After " <u>(xlvii)</u> " strike out "19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione)." and insert " <u>19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione).</u> "
Page 127,	Lines 30 and 31,	After "Norbolethone" strike out "(13{beta}, 17{alpha}-diethyl-17{beta}-hydroxygon-4-en-3-one)." and insert " <u>(13{beta},17{alpha}-diethyl-17{beta}-hydroxygon-4-en-3-one).</u> "
Page 127,	Line 32,	After "Norclostebol" strike out "(4-chloro-17{beta}-hydroxyestr-4-en-3-one)." and insert " <u>(4-chloro-17{beta}-hydroxyestr-4-en-3-one).</u> "
Page 127,	Lines 35 and 36,	After "Normethandrolone" strike out "(17 {alpha}-methyl-17{beta}-hydroxyestr-4-en-3-one)." and insert " <u>(17{alpha}-methyl-17{beta}-hydroxyestr-4-en-3-one).</u> "
Page 127,	Lines 37 and 38,	After "Oxandrolone" strike out "(17{alpha}-methyl-17{beta}-hydroxy-2-oxa- {5{alpha}}-androstan-3-one)." and insert " <u>(17{alpha}-methyl-17{beta}-hydroxy-2-oxa-5{alpha}-androstan-3-one).</u> "
Page 127,	Lines 39 and 40,	After "Oxymesterone" strike out "(17{alpha}-methyl-4, 17 {beta}-dihydroxyandrost-4-en-3-one)." and insert " <u>(17{alpha}-methyl-4,17{beta}-dihydroxyandrost-4-en-3-one).</u> "
Page 127,	Lines 41 and 42,	After "Oxymetholone" strike out "(17 {alpha}-methyl-2-hydroxymethylene-17 {beta}-hydroxy-{5{alpha}}-androstan-3-one)." and insert " <u>(17{alpha}-methyl-2-hydroxymethylene-17{beta}-hydroxy-5{alpha}-androstan-3-one).</u> "
Page 127,	Lines 43 and 44,	After "Stanozolol" strike out "(17{alpha}-methyl-17{beta}-hydroxy-{5{alpha}}- androst-2-eno{3, 2-c}-pyrazole)." and insert " <u>(17{alpha}-methyl-17{beta}-hydroxy-5{alpha}-androst-2-eno{3, 2-c}-pyrazole).</u> "
Page 127,	Lines 45 and 46,	After "Stenbolone" strike out "(17{beta}-hydroxy-2-methyl-{5{alpha}}-androst- 1-en-3-one)." and insert " <u>(17{beta}-hydroxy-2-methyl-5{alpha}-androst-1-en-3-one).</u> "
Page 127,	Lines 47 and 48,	After "Testolactone" strike out "(13-hydroxy-3-oxo-13, 17-secoandrosta-1, 4-dien-17-oic acid lactone)." and insert " <u>(13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone).</u> "
Page 127,	Lines 50 and 51,	After "Tetrahydrogestrinone" strike out "(13{beta}, 17{alpha} -diethyl-17{beta}-hydroxygon-4, 9, 11 -trien-3-one)." and insert " <u>(13{beta},17{alpha}-diethyl-17{beta}-hydroxygon-4,9,11-trien-3-one).</u> "

Page 127,	Line 52,	After "Trenbolone" strike out "(17{beta}-hydroxyestr-4, 9, 11-trien- 3-one)." and insert " <u>(17{beta}-hydroxyestr-4,9,11-trien-3-one).</u> "
Page 128,	Lines 5 and 6,	After "(lxx)" strike out " <u>2{alpha}, 17{alpha}-dimethyl-17{beta}-hydroxy-5{beta}-androstan-3-one.</u> " and insert " <u>2{alpha},17{alpha}-dimethyl-17{beta}-hydroxy-5{beta}-androstan-3-one.</u> "
Page 128,	Line 10,	After "(lxxiii)" strike out " <u>[3,2-c]furazan-5{alpha}-androstan-17{beta}ol.</u> " and insert " <u>{3,2-c}furazan-5{alpha}-androstan-17{beta}-ol.</u> "
Page 128,	Line 13,	After "(lxxvi)" strike out " <u>17{beta}-hydroxy-androstano[2,3-d]isoxazole.</u> " and insert " <u>17{beta}-hydroxy-androstano{2,3-d}isoxazole.</u> "
Page 128,	Line 14,	Before "(lxxvii)" strike out "(" and after "(lxxvii)" strike out " <u>17{beta}-hydroxy-androstano[3,2-e]isoxazole.</u> " and insert " <u>17{beta}-hydroxy-androstano{3,2-c}isoxazole.</u> "
Page 128,	Lines 16 through 18,	After "Methasterone" strike out " <u>(2{alpha},17{alpha}-dimethyl-5{alpha}-androstan-7{beta}-ol-3-one) or 2{alpha}17{alpha}-dimethyl-17{beta}-hydroxy-5{alpha}-androstan-3-one).</u> " and insert " <u>(2{alpha},17{alpha}-dimethyl-5{alpha}-androstan-17{beta}-ol-3-one or 2{alpha}17{alpha}-dimethyl-17{beta}-hydroxy-5{alpha}-androstan-3-one).</u> "
Page 128,	Lines 24 and 25,	After "(lxxxv)" strike out " <u>Prostanozol(17{beta}-hydroxy-5{alpha}-androstano[3,2-e]pyrazole) or [3,2-e]pyrazole-5{alpha}-androstan-17{beta}-ol.</u> " and insert " <u>Prostanozol (17{beta}-hydroxy-5{alpha}-androstano{3,2-c}pyrazole) or {3,2-c}pyrazole-5{alpha}-androstan-17{beta}-ol.</u> "
Page 128,	Line 26,	After "(lxxxvi)" strike out " <u>[3,2-c]pyrazole-androst-4-en-17{beta}-ol.</u> " and insert " <u>{3,2-c}pyrazole-androst-4-en-17{beta}-ol.</u> "
Page 129,	Line 9,	After "Perampanel" insert " <u>, its salts, isomers and salts of isomers"</u>
Page 129,	Line 10,	After "of isomers" insert " <u>, except when expressly intended for use by a veterinarian in the course of the professional practice of veterinary medicine; provided, however, that such substance stocks shall be at all times properly safeguarded and secured, and access shall be limited to the minimum number of employees actually required to efficiently handle the custody, dispensing, administration or other handling of such substance; and further provided, however, that all veterinarians shall maintain records, orders and prescriptions of the substance for a period of five years from the date of transaction, which shall</u>

		be readily available and promptly produced, in electronic or hardcopy format that is readily understandable, for inspection and copying upon request by authorized representatives of the department. Any individual who knowingly and willfully administers themselves or another person, prescribes, dispenses or distributes such substance when any such substance is intended for human consumption or for any purpose other than the normal course of practice of veterinary medicine shall be subject to the same penalties as any individual or practitioner who violates the provisions of this section and any other penalties prescribed by law"
Page 129,	Line 22,	After "by" insert "amending paragraph 10 and"
Page 129,	Between lines 23 and 24,	Insert "(10) SPA((-)[])-1-dimethylamino-1,2-diphenylethane)."
Page 129,	Line 25,	After "Solriamfetol." insert "(2-amino-3-phenylpropyl carbamate; benzenepropanol, beta-amino-, carbamate(ester))."
Page 129,	Lines 39 through 41,	After "Eluxadoline." strike out "(5-(((2S)-2-amino-3-(4-aminocarbonyl)-2,6-dimethylphenyl)-1-xopropyl){(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl}amino)methyl}-2-methoxybenzoic acid)." and insert "(5-(((2S)-2-amino-3-(4-(aminocarbonyl)-2,6-dimethylphenyl)-1-oxopropyl){(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl}amino)methyl}-2-methoxybenzoic acid) (including its optical isomers) and its salts, isomers, and salts of isomers."
Page 129,	Lines 46 and 47,	After "Brivaracetam" strike out "((2S)-2-((4R)-2-oxo-4-propylpyrrolidin-1-yl) butanam-ide)." and insert "((2S)-2-((4R)-2-oxo-4-propylpyrrolidin-1-yl) butanamide)."
Page 129,	Lines 50 and 51,	After "2H-tetrazole-2-ethanol," strike out " alpha-(2-chlorophenyl)-, carbamate(ester)," and insert "alpha-(2-chlorophenyl)-, carbamate(ester),"
Page 129,	Line 53,	After "Ganaxolone." strike out "3@-hydroxy-3&-methyl-5@-pregnan-20-one." and insert "3{alpha}-hydroxy-3{beta}-methyl-5{alpha}-pregnan-20- one."
Page 132,	Lines 15 and 16,	After "chapter" strike out "and authorize pursuant to section three thousand eighteen of this chapter to provide community paramedicine"
Page 134,	Line 52,	After "15" strike out "Notwithstanding" and insert "Subject to the availability of federal financial participation and notwithstanding"
Page 134,	Line 54,	After "off-site" strike out "primary care and" insert "acute care" and after "medical" strike out "care"

Page 134,	Line 55,	Strike out " <u>including but not limited to acute care and preventative wellness care,</u> "
Page 135,	Line 4,	After " <u>a</u> " strike out " <u>primary care</u> " insert " <u>medical</u> "
Page 135,	Line 5,	After " <u>registered nurse,</u> " insert " <u>nurse practitioner,</u> "
Page 135,	Line 8,	After " <u>patient</u> " strike out " <u>who is unable to leave his or her residence</u> " and insert " <u>for whom a medical professional has determined is appropriate to receive acute medical services at their residence</u> "
Page 135,	Lines 9 through 11,	Strike out " <u>to receive services at the general hospital without unreasonable difficulty due to circumstances, including but not limited to, clinical impairment and conditions of immunosuppression</u> "
Page 135,	Line 36,	After " <u>not</u> " strike " <u>lawfully</u> " and insert " <u>currently approved and</u> " and after " <u>operating</u> " strike out " <u>and established pursuant to</u> " and insert " <u>in accordance with</u> "
Page 135,	Line 43,	After " <u>or</u> " strike out " <u>expanded</u> " and insert " <u>modified</u> "
Page 135,	Line 46,	After " <u>paragraph</u> " strike out " <u>shall</u> " and insert " <u>may</u> "
Page 137,	Line 24,	After " <u>services</u> " insert " <u>by an EMS medical dispatch agency</u> "
Page 137,	Line 30,	After " <u>needed</u> " insert " <u>, except for any such individual or entity that is subject to minimum standards promulgated under section three-hundred twenty-eight of County Law</u> "
Page 137,	Line 47,	After " <u>plan</u> " strike out " <u>, in a format</u> "
Page 137,	Line 49,	After " <u>coordination,</u> " insert " <u>utilization of existing ambulance services licensed by the Department,</u> "
Page 137,	Line 54,	After " <u>county.</u> " insert " <u>Any proposed permanent changes, including a full closure or significant modification of coverage of a primary medical emergency response agency designated by a county shall be submitted in writing to the county and the department no later than 180 days before the change. Such changes shall not be made until receipt of the appropriate department approval. No county shall remove or reassign an area served by an existing medical emergency response agency where that agency is compliant with all statutory and regulatory requirements of the department, and that has agreed to the provision of approved plan.</u> "
Page 138,	Line 42,	After " <u>Every</u> " strike out " <u>emergency</u> " and insert " <u>EMS</u> "

Page 138,	Line 43,	After " <u>agency</u> " insert ", <u>as defined in this section,</u> "
Page 138,	Line 44,	After " <u>with</u> " insert " <u>emergency medical dispatch</u> "
Page 138,	Line 46,	After " <u>All</u> " strike out " <u>emergency</u> " and insert " <u>EMS</u> " and after " <u>agencies</u> " strike out " <u>shall</u> " and insert " <u>may be required to</u> "
Page 138,	Line 47,	After " <u>The department</u> " strike out " <u>shall</u> " insert ", <u>in consultation with the State Interoperable Emergency Communications Board, may</u> "
Page 138,	Line 48,	Before " <u>medical</u> " strike out " <u>emergency</u> " and insert " <u>EMS</u> " and after " <u>agencies</u> " insert ", <u>as defined in this section,</u> " and after " <u>with</u> " strike out " <u>emergency</u> " and insert " <u>EMS</u> "
Page 138,	Line 50,	After " <u>dispatchers</u> " insert " <u>with a primary role of providing emergency medical dispatch services while</u> " and after " <u>by</u> " strike out " <u>emergency</u> " insert " <u>EMS</u> "
Page 138,	Line 51,	After " <u>agencies</u> " insert ", <u>as defined in this section,</u> " and after " <u>complete</u> " strike out " <u>a</u> " insert " <u>an emergency medical dispatch</u> "
Page 138,	Line 52,	After " <u>department</u> " insert ", <u>in consultation with the State Interoperable Emergency Communications Board,</u> "
Page 138,	Line 53,	After " <u>the</u> " strike out " <u>emergency</u> " and insert " <u>EMS</u> " and after " <u>agency</u> " insert ", <u>as defined in this section, with a primary role</u> "
Page 138,	Line 54,	After " <u>dispatcher</u> " insert ", <u>and may be required to be licensed by the department</u> " and after " <u>department</u> " strike out " <u>shall</u> " and insert ", <u>in consultation with the State Interoperable Emergency Communications Board, may</u> "
Page 138,	Line 55,	After " <u>dispatch</u> " insert " <u>certification</u> " and after " <u>dispatcher</u> " strike out " <u>certification</u> " and insert " <u>licensure</u> "
Page 139,	Line 38,	After " <u>to</u> " strike out " <u>evaluate</u> " and insert " <u>effectuate</u> "
Page 141,	Line 12 through line 24,	Strike out "Section 1. Section 5 of part NN of chapter 57 of laws of 2018 amending the public health law and other laws relating to the opioid stewardship act, as amended by section 5 of part XX of chapter 59 of the laws of 2019, is amended to read as follows: § 5. This act shall take effect July 1, 2018 and sections one, two and four of this part shall expire and be deemed to be repealed on June 30, 2024, provided that, effective immediately, the addition, amendment and/or repeal of any rule or regulation necessary for the implementation of this act on its effective date

		are authorized to be made and completed on or before such effective date, and, provided that this act shall only apply to the sale or distribution of opioids in the state of New York on or before December 31, 2018.§ 2. This act shall take effect immediately." and insert "Intentionally Omitted."
Page 146,	Line 10 through line 11,	After "services;" strike out "basic home and community based services (HCBS) plan support;"
Page 147,	Between lines 25 and 26,	Insert New Part GG (LBD #71037-01-4) Insert New Part HH (LBD #71016-05-4)
Page 147,	Line 36,	After "through" strike out "FF" and insert "HH"